Anthera Pharmaceuticals (Anthera Pharmaceuticals) EPS (Basic) : $-1.70 (TTM As of Mar. 2018)

View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals EPS (Basic)?

Anthera Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2018 was $-0.42. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2018 was $-1.70.

Anthera Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2018 was $-0.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2018 was $-1.70.

Anthera Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2018 was $-0.57. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2018 was -2.49.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Anthera Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Anthera Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals EPS (Basic) Chart

Anthera Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EPS (Basic)

Get a 7-Day Free Trial

-13.52

-10.88

-7.91

-12.87

-2.86

Anthera Pharmaceuticals Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
EPS (Basic)	Get a 7-Day Free Trial															-2.03	0.03	-0.58	-0.73	-0.42

Anthera Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Anthera Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2017 is calculated as

Basic EPS (A: Dec. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-26.874	-	2.503)	/	10.278
	=	-2.86

Anthera Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2018 is calculated as

Basic EPS (Q: Mar. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.724	-	1.54)	/	22.167
	=	-0.42

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.70

Anthera Pharmaceuticals (OTCPK:ANTH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Anthera Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545

Website

http://www.anthera.com

Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.

Executives

Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr	officer: Chief Medical Officer	10301 STELLA LINK HOUSTON TX 77025
Brian Mueller	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex	director	PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson	officer: Chief Technology Officer	25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson	officer: Chief Regulatory Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle	director	C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington	officer: Interim Chief Medical Officer	25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin	officer: Chief Medical Officer	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe	officer: CFO and Chief Business Officer	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines

From GuruFocus

Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets

By Marketwired Marketwired • 06-27-2018

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2010

Major US Indexes End Higher Monday

By Julie Young • 11-08-2021

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-14-2010

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-12-2010